Contemporary outcomes of acute ischemic stroke in atrial fibrillation patients on anticoagulation.
Research article published in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2024)
Abstract
BACKGROUND: Long-term anticoagulation (AC) therapy reduces the risk of stroke in patients with Atrial Fibrillation (AF). However, data on the impact of AC on in-hospital stroke outcomes is lacking. METHODS: The National Inpatient Sample was used to identify adult inpatients with AF and a primary diagnosis of ischemic stroke between 2016 and 2020. Data was stratified between AC users and nonusers. A multivariate regression model was used to describe the in-hospital outcomes, adjusting for significant comorbidities. RESULTS: A total of 655,540 hospitalizations with AF and a primary hospitalization diagnosis of ischemic stroke were included, of which 194,560 (29.7 %) were on long-term AC. Patients on AC tended to be younger (mean age, 77 vs. 78), had a higher average CHA2DS2VASc score (4.48 vs. 4.20), higher rates of hypertension (91 % vs. 88 %), hyperlipidemia (64 % vs. 59 %), and heart failure (34 % vs. 30 %) compared to patients not on long-term AC. Use of AC was associated with decreased in-hospital mortality (aOR [95 % CI]: 0.62 [0.60-0.63]), decreased stroke severity (mean NIHSS, 8 vs. 10), decreased use of tPA (aOR 0.42 [0.41-0.43]), mechanical thrombectomy (aOR 0.85 [0.83-0.87]), intracranial hemorrhage (aOR 0.69 [0.67-0.70]), gastrointestinal bleeding (aOR 0.74 [0.70-0.77]), and discharge to skilled nursing facilities (aOR 0.90 [0.89-0.91]), compared to patients not on AC (P<0.001 for all comparisons). CONCLUSION: Among patients with AF admitted for acute ischemic stroke, AC use prior to stroke was associated with decreased in-hospital mortality, decreased stroke severity, decreased discharge to SNF, and fewer stroke-related and bleeding complications.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Long-term anticoagulation (AC) therapy reduces the risk of stroke in patients with Atrial Fibrillation (AF). However, data on the impact of AC on in-hospital stroke outcomes is lacking. The National Inpatient Sample was used to identify adult inpatients with AF and a primary diagnosis of ischemic stroke between 2016 and 2020. Data was stratified between AC users and nonusers.
Warum dies für die Hirudotherapie relevant ist
Unter Verwendung des U.S. National Inpatient Sample (2016–2020) untersuchte diese Analyse 655.540 Krankenhausaufenthalte von Vorhofflimmern-Patienten, die wegen eines ischämischen Schlaganfalls aufgenommen wurden, und fand, dass eine vorbestehende langfristige Antikoagulation (bei 29,7% der Patienten) mit einer geringeren Krankenhaussterblichkeit (adjustiertes OR 0,62), einem geringeren Schweregrad des Schlaganfalls sowie weniger intrakraniellen Blutungs- und gastrointestinalen Blutungskomplikationen im Vergleich zu Nichtanwendern verbunden war. Für ASH untermauert dies, warum antikoagulatorische Signalwege ein zentrales Ziel der Wirkstoffforschung sind und warum das Blutegel-Sekretom, das antikoagulatorische und antithrombotische Moleküle enthält, die auf dasselbe Gerinnungssystem wirken, pharmakologisch untersucht wird. Als retrospektive Studie auf Basis einer administrativen Datenbank zeigt sie eine Assoziation, keine Kausalität, ist trotz Adjustierung anfällig für Confounding und betrifft konventionelle orale Antikoagulanzien, nicht Blutegel oder Hirudotherapie.
Zitation
Contemporary outcomes of acute ischemic stroke in atrial fibrillation patients on anticoagulation.
Vasquez et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2024
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026